In the realm of personalized medicine, the role of genetic testing in cancer treatment has become increasingly significant. Among the forefront of these advancements are the Oncomine Comprehensive Panel and the Oncomine Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and Programmed Death-Ligand 1 (PD-L1) tests. These tests are pivotal in identifying genetic mutations and alterations that can influence treatment decisions for cancer patients. At DNA Labs UAE, we are dedicated to providing these state-of-the-art tests, which are available for AED 24,000. For more information, please visit our website at DNA Labs UAE.
Symptoms and Indications for Testing
The Oncomine tests are not directly related to symptoms in the traditional sense but are crucial for patients who have been diagnosed with cancer. These tests are particularly recommended for individuals who have advanced cancer, cancer that has not responded to standard treatments, or a type of cancer known to have genetic mutations that can be targeted by specific therapies. The decision to use these tests is often based on factors such as the type and stage of cancer, previous treatment history, and overall health status of the patient.
Understanding the Tests
The Oncomine Comprehensive Panel is a next-generation sequencing (NGS) test that screens for hundreds of genetic mutations across multiple cancer genes. This comprehensive approach allows oncologists to identify specific mutations in a patient’s cancer cells, providing a clearer understanding of the cancer’s behavior and how it might respond to targeted therapies.
The Oncomine Tumor Mutation Burden (TMB) test measures the number of mutations within a tumor’s genome. A high TMB is associated with a better response to immunotherapy, making this test a valuable tool in deciding whether immunotherapy is a suitable treatment option.
Similarly, the Microsatellite Instability (MSI) test detects abnormalities in the DNA repair process that may lead to cancer. Cancers with high MSI are more likely to respond to certain immunotherapies.
The PD-L1 test evaluates the expression of the PD-L1 protein on the surface of cancer cells. PD-L1 plays a key role in suppressing the immune response, and its presence can influence the effectiveness of immunotherapies designed to block this interaction.
Benefits of the Oncomine Tests
-
Precision Medicine: These tests provide detailed genetic profiles of tumors, enabling personalized treatment plans that target specific genetic mutations.
-
Improved Treatment Outcomes: By identifying the most effective treatments based on a tumor’s genetic makeup, these tests can improve response rates and, in some cases, reduce the risk of side effects.
-
Advanced Insights: The comprehensive nature of the Oncomine Comprehensive Panel offers insights into rare and common mutations alike, broadening the scope of potential treatment options.
Test Cost
The cost of the Oncomine Comprehensive Panel and Oncomine Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and PD-L1 tests at DNA Labs UAE is AED 24,000. This investment in your health provides access to cutting-edge genetic testing that can significantly influence your cancer treatment plan.
Understanding the genetic landscape of a tumor is crucial in the era of personalized medicine. The Oncomine tests offer a comprehensive approach to identifying the genetic alterations that drive cancer growth, allowing for more targeted and effective treatments. At DNA Labs UAE, we are committed to providing our patients with the most advanced diagnostic tools to support their fight against cancer. For more information on these tests, please visit our website.
For more detailed information and to schedule a test, please visit DNA Labs UAE.
